Evidence map›Paper›PMID 31695469›Full record

ArticleClinical and experimental gastroenterology2019

Cholestasis In Infants With Down Syndrome Is Not Due To Extrahepatic Biliary Atresia: A Ten-Year Single Egyptian Centre Experience.

Magd A Kotb, Iman Draz, Christine Ws Basanti, Sally Tm El Sorogy, Hesham M Abd Elkader, Haytham Esmat, Hend Abd El Baky, Dalia Sayed Mosallam

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Editorial: Elimination of biliary atresia.Frontiers in pediatrics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Magd A KotbPediatrics Department, Faculty of Medicine, Kasr Al Ainy, Cairo University, Cairo, Egypt.ORCID 0000-0001-5928-8684
Iman DrazPediatrics Department, Faculty of Medicine, Kasr Al Ainy, Cairo University, Cairo, Egypt.
Christine Ws BasantiPediatrics Department, Faculty of Medicine, Kasr Al Ainy, Cairo University, Cairo, Egypt.ORCID 0000-0002-3149-9233
Sally Tm El SorogyPediatrics Department, Public Mounira Hospital, Cairo, Egypt.
Hesham M Abd ElkaderDepartment of Pediatric Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID 0000-0002-5612-1157
Haytham EsmatDepartment of Pediatric Surgery, Cairo University, Cairo, Egypt.
Hend Abd El BakyPediatrics Department, Faculty of Medicine, Kasr Al Ainy, Cairo University, Cairo, Egypt.
Dalia Sayed MosallamPediatrics Department, Faculty of Medicine, Kasr Al Ainy, Cairo University, Cairo, Egypt.
Cairo University · EGAin Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to define the clinical presentations, course and outcome of cholestasis in infants with Down syndrome (trisomy 21) who presented to the Pediatric Hepatology Clinic, New Children Hospital, Cairo University, Egypt.

methodsRetrospective analysis of data of cohort of infants with Down syndrome and cholestasis who followed up during 2005-2015.

resultsAmong 779 infants with cholestasis who presented during 2005-2015, 61 (7.8%) had Down syndrome. Six dropped out. Among the 55 who followed-up for a mean duration +SD = 12.1 ± 16.7 months, none had extrahepatic biliary atresia (EHBA), 37 (63.3%) had neonatal hepatitis and 18 (32.7%) had non-syndromic paucity of intrahepatic biliary radicals. Fourteen (25.4%) had associated congenital heart disease. Only 35 (63.3%) cleared the jaundice. Twenty-nine (52.7%) received ursodeoxycholic acid (UDCA); of them, 13 cleared the jaundice, one improved, 14 progressed and one died, compared to 22 who cleared the jaundice of the 26 who did not receive UDCA. Only three of those who did not receive UDCA progressed and none died. UDCA carried a 3.4-fold risk of poor prognosis (

conclusionWe did not come across EHBA among neonates and infants with Down syndrome in 10 years. Non-syndromic paucity is associated with favorable outcome in infants with Down syndrome. UDCA use in cholestasis with Down syndrome is associated with poor outcome.

Indexed as

cholestasisDown syndromeEHBAextrahepatic biliary atresianeonatal hepatitistrisomy 21UDCAursodeoxycholic acid

Identifiers

PMID31695469
PMCPMC6815214
OpenAlexW2981271033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.